Adenoidectomy for Otitis Media in 2-3 Year Old Children

Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD) (NIH)
Overall Status
Terminated
CT.gov ID
NCT00016497
Collaborator
(none)
1
119

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the efficacy of three different surgical treatments (1. Bilateral myringotomy and tube insertion (M&T); 2. Adenoidectomy and bilateral myringotomy (A&T); 3. Adenoidectomy with myringotomy and tympanostomy tube insertion (A-M&T)) in reducing subsequent episodes of middle ear disease and hearing loss caused by the fluid in the middle ear in children aged 24-47 months. The fluid in the middle ear is of at least three months' duration and unresponsive to standardized, recent antimicrobial treatment. The children are assigned to one of the three surgical treatments. After surgery, they are followed with examinations monthly and at the time of intercurrent infections for three years.

Condition or Disease Intervention/Treatment Phase
  • Procedure: bilateral myringotomy
  • Procedure: bilateral myringotomy and tubes
  • Procedure: adenoidectomy
Phase 3

Detailed Description

The specific aim of this study is to compare, by means of a randomized clinical trial, the efficacy of three surgical treatment combinations: adenoidectomy with myringotomy (A-M), adenoidectomy with myringotomy and tympanostomy tube insertion (A-M&T), and M&T alone, in reducing subsequent middle ear disease in children aged 24-47 months with otitis media with effusion (OME) of at least 3 months' duration unresponsive to standardized, recent antimicrobial treatment. The children are randomly assigned to one of three treatment arms:

  1. M&T; 2. A-M; and 3. A-M&T. Subjects are be stratified according to: 1. age; 2. nasal obstruction; and 3. previous tubes. All subjects are scheduled for surgery according to assignment within 4 weeks after entry. The first post-operative visit takes place 2 weeks after surgery, and a complete examination of the ears, nose, and throat (ENT exam) including pneumatic otoscopy, tympanometry and audiometry is performed. Subjects are followed with monthly evaluations (ENT-exam, pneumatic otoscopy, tympanometry) for three years. Audiometry is performed every 6 months. All subjects are evaluated at any time while still enrolled in the study if signs and symptoms of URI, acute otitis media (AOM, including otorrhea), or OME occur and are treated appropriately. Subjects who develop OME for 4 months bilaterally or 6 months unilaterally have M&T and continue to be followed in the study. The primary outcome measure will be percentage of time with middle ear effusion (MEE). Episodes of AOM, otorrhea, and OME, time to first recurrence, and number of surgical procedures will be compared between the three treatment groups. Treatment failures, complications and sequelae of treatments will also be recorded and compared among the three treatment groups.

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Primary Purpose:
Treatment
Official Title:
Adenoidectomy for Otitis Media in 2-3 Year Old Children
Study Start Date :
Feb 1, 1997
Study Completion Date :
Jan 1, 2007

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    24 Months to 47 Months
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    • Males and females between 24 and 47 months of age, in good general health.

    • Asymptomatic otitis media with effusion bilaterally for a minimum of 3 consecutive months.

    • At least one 10-day course of a broad-spectrum antimicrobial agent in the last month.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ear, Nose, and Throat Research Center, Children's Hospital of Pittsburgh Pittsburgh Pennsylvania United States 15213-2583

    Sponsors and Collaborators

    • National Institute on Deafness and Other Communication Disorders (NIDCD)

    Investigators

    • Principal Investigator: Margaretha L Casselbrant, University of Pittsburgh

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00016497
    Other Study ID Numbers:
    • NIDCD1RO1DC035-04
    First Posted:
    May 14, 2001
    Last Update Posted:
    Apr 24, 2006
    Last Verified:
    Apr 1, 2006

    Study Results

    No Results Posted as of Apr 24, 2006